2025-06-01
P-729 Cost-effectiveness of follitropin delta versus follitropin alfa for controlled ovarian stimulation for IVF/ICSI in China
2025-06-01 • Shasha Han, Rui Yang, Xiaodong Guan, Jacques Carette, Mathias Markert, Chaojie Liu, Jie Qiao
Abstract Study question Is follitropin delta cost-effective compared with follitropin alfa for controlled ovarian stimulation (COS) for IVF/ICSI in China? Summary answer Follotropin delta leads to higher live birth rates at lower costs compared with follitropin alfa, making it a dominant treatment option (higher effect, lower cost). What is known already Follitropin delta for injection (REKOVELLE) was approved by Chinese authorities in April 2024. Follitropin delta is associated with higher serum levels of FSH and…